Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

UBS raised the firm’s price target on Amgen (AMGN) to $319 from $315 and keeps a Neutral rating on the shares. The firm is expecting an in-line ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

US biotech giant Amgen (Nasdaq: AMGN) today announced a significant breakthrough with its global Phase III DeLLphi-304 ...

PROTEOR, a global leader in prosthetics and orthotics (O&P), announced today the expansion of its Digital solutions and a first-in-the-industry innovation:  The production of non-vase mode definitive ...

Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...